You just read:

Oncotype DX® Genomic Prostate Score™ Test Increases Use of Active Surveillance by 30 Percent in Low-risk Patients, Resulting in Greater Adherence to Guideline-based Care

News provided by

Genomic Health, Inc.

Feb 05, 2018, 08:00 ET